

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7192996

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SHIRE HUMAN GENETICS THERAPIES, INC.	02/10/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TAKEDA PHARMACEUTICAL COMPANY LIMITED
<b>Street Address:</b>	1-1, DOSHOMACHI 4-CHOME
<b>Internal Address:</b>	CHUO-KU
<b>City:</b>	OSAKA
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	540-8645
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17116098
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)526-9899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6175299780
<b>Email:</b>	lgjachinta@proskauer.com
<b>Correspondent Name:</b>	PROSKAUER ROSE LLP
<b>Address Line 1:</b>	ONE INTERNATIONAL PLACE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	SHR-2011US1
<b>NAME OF SUBMITTER:</b>	NICHOLAS C. PRAIRIE
<b>SIGNATURE:</b>	/Nicholas C. Prairie/
<b>DATE SIGNED:</b>	02/24/2022
<b>Total Attachments: 2</b>	
source=SHR-2011US1 - Executed Assignment (SHGT to TPC)#page1.tif	
source=SHR-2011US1 - Executed Assignment (SHGT to TPC)#page2.tif	

**ASSIGNMENT**

In accordance with the **Intercompany Agreement on Assignment of Legal Title to Patents** dated effective as of April 1<sup>st</sup>, 2020 (the "Agreement"), made by and between Shire Human Genetics Therapies, Inc., a company organized under the laws of Delaware, having a place of business at 300 Shire Way, Lexington, Massachusetts ("ASSIGNOR"), and TAKEDA PHARMACEUTICAL COMPANY LIMITED, a company organized under the laws of Japan, having a place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 Japan ("ASSIGNEE"), ASSIGNOR confirms its transfer and assignment to ASSIGNEE of legal title to the patent or patent application, and inventions (as defined in 35 USC Sec. 100) in such patent or patent application ("Inventions"), identified below...

*ADENO ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF HUNTER DISEASE;*

- prepared for filing in the United States Patent and Trademark Office; or
- identified by United States Application No. *17/116,098* filed in the United States Patent and Trademark Office on *December 9, 2020*; and
- identified by Taiwan Application No. *109143730* filed in the Taiwan Patent and Trademark Office on *December 10, 2020*; and
- identified by Lebanon Application No. *3378* filed in the Lebanon Patent and Trademark Office on *December 8, 2020*; and
- identified by Gulf Cooperation Council (GCC) Application No. *2020/41069* filed in the GCC Patent and Trademark Office on *December 8, 2020*; and
- identified by Argentina Application No. *P200103430* filed in the Argentina Patent and Trademark Office on *December 10, 2020*; and
- identified by International Patent Application No. *PCT/US2020/063887* filed on *December 9, 2020*; and
- is also aware of the following priority applications:  
  
Serial No.: *62/945,920*; Filed: *December 10, 2019*

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, the receipt of which is hereby acknowledged, ASSIGNOR hereby confirms and/or declares that it holds legal title to the patent application, the same to be held and enjoyed by ASSIGNEE, its successors and assigns, in and to any and all Inventions described in the patent application, and/or any priority applications noted above. Assignor hereby confirms that assignment and transfer of such legal title is and was effective not later than the filing date of the patent or patent application and/or priority application. ASSIGNOR'S assignment and transfer applies to the above-referenced patent or patent application, any Inventions disclosed and/or claimed in this patent or patent application, any and all patents and patent applications arising from such application and any


addition, division, continuation, continuation in part, substitution, extension, renewal, reissue, confirmation thereof, including their patent term adjustments (PTA), extensions (PTE) or supplementary protection certificates (SPC). Such legal title includes the right to claim the priority of the said applications in any applicable country in connection with filing a patent application in any applicable country. Also, this assignment and transfer pertains to any legal title ownership rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including: (i) all rights of priority under the International Convention for the Protection of Industrial Property; (ii) in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued. ASSIGNEE shall hold and enjoy legal title in said Inventions, applications, and patent(s) for its own use and for its successors, assigns and legal representatives, to the full end of term for which said patent(s) may be granted and extended by any patent term adjustment, extension or supplemental protection certificate.

AND, ASSIGNOR hereby acknowledges that this assignment carries with it the right in ASSIGNEE to apply for, and receive Legal Title to, any and all patent(s) for said Inventions in ASSIGNEE'S own name;


IN TESTIMONY WHEREOF, ASSIGNOR by its duly authorized representative acting on his/her own free will have caused this instrument to be duly executed and have hereunto set his/her hand and affixed his/her seal on the date set forth below.

SIGNED this 10<sup>th</sup> day of February, 2022.

ASSIGNOR

By:   
Name: Maya Cole  
Title: IP Region Head

TAKEDA PHARMACEUTICAL COMPANY LIMITED

By:   
Name: Constance Yeung  
Title: IP Region Head